Fig. 4
ERK5 inhibition enhances vomocytosis and reduces dissemination in a zebrafish model of cryptococcosis.
(A) Infected zebrafish treated with XMD17-109 show a significant (P = 0.001, Fisher’s exact test) increase in vomocytosis in vivo over 24 hours. Bars represent the median and 5th/95th percentile. (B) Overall fungal burden at 3 days after infection is not significantly altered by ERK5 inhibition. Bars represent the median and 5th/95th percentile, with the boxed region representing the interquartile range. (C) Individual infections can be individually scored as nondisseminated (restricted to the bloodstream; top), disseminated to muscle/tissue blocks (middle), or disseminated to the central nervous system (bottom). CNS, central nervous system. (D) Infected fish treated with XMD17-109 show significantly (P < 0.05, Fisher’s exact test) reduced dissemination from the site of infection. Bars represent the median and 5th/95th percentile.